Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MP0274 · 1 trial · 1 indication
Number and grading according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)
| Arm | Type | Description |
|---|---|---|
| MP0274 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| MP0274 | DRUG | Intravenous infusion of MP0274 as single agent at four planned dose levels, every three weeks until progressive disease, unacceptable toxicity or patient withdrawal for other reasons |
INCLUSION CRITERIA 1. Have signed and dated written informed consent prior to performing any study procedure, including screening 2. Are ≥ 18 years old on the day of signing informed consent 3. Have histologically confirmed and documented HER2 positive solid tumor malignancy that is unresectable, l...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
MP0274 is an investigational small molecule being developed for the treatment of neoplasms, which are abnormal growths of tissue that can be cancerous. It is being studied in patients with HER2-positive solid tumors, as part of a first-in-human clinical trial.
MP0274 is being developed by Molecular Partners AG, a biopharmaceutical company. The company's stock is traded under the ticker symbol MOLN. The drug is currently in Phase 1 clinical development.
MP0274 is in Phase 1 clinical development. It has completed a first-in-human study, and it remains an investigational drug. It has not been approved by regulatory authorities and is still being evaluated for safety and activity in clinical trials.
MP0274 has been studied in one clinical trial, identified as NCT03084926. This was a first-in-human study that investigated the safety, blood levels, and activity of MP0274 in cancer patients with HER2-positive solid tumors. The trial has been completed.
MP0274 is a distinct investigational drug candidate developed by Molecular Partners AG. It is not known to be the same as any other approved or marketed drug. It is being studied specifically for its potential effects in HER2-positive solid tumors.